Page last updated: 2024-08-16

temozolomide and xanthenes

temozolomide has been researched along with xanthenes in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Arcella, A; Battaglia, G; Bonelli, M; Ciceroni, C; De Maria, R; Larocca, LM; Laurenza, M; Mastrantoni, E; Melchiorri, D; Niccolini, C; Nicoletti, F; Pallini, R; Ricci-Vitiani, L; Spinsanti, P; Traficante, A1
Beck, J; Behringer, SP; Follo, M; Garrelfs, N; Goeldner, JM; Hannibal, L; Heiland, DH; Hofmann, UG; Joseph, K; Kueckelhaus, J; Maier, JP; Pfeifer, D; Ravi, VM; Schnell, O; Sun, N; von Ehr, J; Walch, AK; Will, P1

Other Studies

2 other study(ies) available for temozolomide and xanthenes

ArticleYear
Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.
    Cell death and differentiation, 2013, Volume: 20, Issue:3

    Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Neoplastic Stem Cells; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Receptors, Metabotropic Glutamate; RNA, Messenger; Signal Transduction; Survival Rate; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xanthenes

2013
Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma.
    Cell death & disease, 2021, 07-21, Volume: 12, Issue:8

    Topics: Amino Acids; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Glutamic Acid; Humans; Kinetics; Neoadjuvant Therapy; Receptors, Metabotropic Glutamate; Temozolomide; Tumor Microenvironment; Xanthenes

2021